Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197739 | 0.80 | CHRNA7 (0.46) | CHRNA7IDH1KDM5BPSEN1PSEN2 | |
| SCHEMBL22404460 | 0.80 | LMNA (0.42) | ESR1ESR2 | |
| SCHEMBL25935036 | 0.74 | NPSR1 (0.39) | IDH1KDM5BDGKZ | |
| SCHEMBL14580443 | 0.74 | CHRNA7 (0.43) | CHRNA7IDH1KDM5B | |
| SCHEMBL21864515 | 0.73 | CHRNA7 (0.43) | CHRNA7IDH1KDM5B | |
| SCHEMBL18407481 | 0.73 | CHRNA7 (0.43) | CHRNA7IDH1KDM5B | |
| SCHEMBL10470957 | 0.72 | MAPT (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10470958 | 0.72 | MAPT (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL828068 | 0.71 | GABRP (0.40) | ESR1ESR2 | |
| SCHEMBL24409539 | 0.71 | TRPV3 (0.40) | CHRNA7IDH1KDM5BPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CHRNA7 4323/4885ESR1 3766/4885ESR2 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.